Clinical Trial: Asciminib and Inotuzumab Ozogamicin for Relapsed or Refractory Philadelphia Chromosome-positive B-cell Acute Lymphoblastic Leukemia (R/R Ph+ B-ALL)

U.S., Nov. 14 -- ClinicalTrials.gov registry received information related to the study (NCT07936266) titled 'Asciminib and Inotuzumab Ozogamicin for Relapsed or Refractory Philadelphia Chromosome-positive B-cell Acute Lymphoblastic Leukemia (R/R Ph+ B-ALL)' on Oct. 27.

Brief Summary: This is a multi-center phase 1 open-label study to determine the safety of ABL001 and INO in patients with relapsed or refractory Philadelphia chromosome-positive b-cell acute lymphoblastic leukemia.

Study Start Date: March 31, 2027

Study Type: INTERVENTIONAL

Condition: B-cell Acute Lymphoblastic Leukemia (B-ALL)

Intervention: DRUG: Asciminib

Asciminib is a first-in-class STAMP (Specifically Targeting the ABL Myristoyl Pocket), and is an approved TKI in...